Cancer control : journal of the Moffitt Cancer Center
NCCN: Multiple myeloma
Contenu en anglais
Résumé
Although multiple myeloma is sensitive to both chemotherapy and RT, it remains incurable at present. However, treatment algorithms based on published data, as well as clinical experience, can be developed to optimize therapy. This includes not only therapy for the underlying disease but also supportive therapy to enhance quality of life. Because myeloma is incurable, these guidelines prominently identify the clinical settings appropriate for treatment of patients on clinical research protocols.
Source et droits
Publiée par Cancer control : journal of the Moffitt Cancer Center, 2001. La recommandation elle-même se trouve à la source indiquée ici.
Prognia résume cette recommandation à des fins de consultation et d’enseignement. Il ne s’agit pas d’un avis médical. Vérifiez toujours la recommandation officielle et les protocoles locaux en vigueur avant de l’appliquer.
En bref
- Date de publication
- 2001
- S’applique à
- 🇺🇸 États-Unis
- Portée
- Nationale
- Revue
- Cancer control : journal of the Moffitt Cancer Center
- PubMed
- 11760563
- Ajout sur Prognia
- 25 juillet 2026
Autres recommandations en hématologie
- Perceived relative clinical significance of the risks of venous thromboembolism and bleeding from pharmacologic thromboprophylaxis in children: an international survey of pediatric providers: communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and HemostasisInternational Society on Thrombosis and Haemostasis · 2026
- Evidence-based AGIHO guideline update on prophylaxis of infectious complications with granulocyte-stimulating factors (G-CSF) for the treatment of adult patients with cancerInfectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) · 2026
